Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies.

However, although patients with KMT2Ar and hypodiploidy also showed a trend toward higher response rates, this did not translate into a statistically significant PFS benefit, suggesting that while these subgroups may respond to inotuzumab, they remain at high risk of relapse [ 24 ]. 2.1.4 Inotuzumab in MRD ‐Positive Patients Recently a phase 2 study explored the safety and efficacy of inotuzumab ozogamicin in MRD‐positive patients.

also in 53,322 other papers